Companies ›Healthcare ›4884.T

4884.T — Tokyo Stock Exchange Biotechnology & Medical Research

Kringle Pharma Inc

¥293,00

Open in Charts → Attach watcher ⌖

— —

JPY

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

0,00 %

Op margin

-814,1 %

ROE

-8,5 %

Net margin

-808,3 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Kringle Pharma Inc is a biotechnology company focused on healthcare diagnostics, developing and commercializing diagnostic solutions to identify and monitor health conditions.

Business. Kringle Pharma Inc (4884.T) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is listed on the Tokyo Stock Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-8,5 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 4884.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 4884.T. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Kringle Pharma Inc (4884.T) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is listed on the Tokyo Stock Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

AI synthesis

GENERATED

Kringle Pharma Inc has a highly liquid capital structure, with cash and equivalents amounting to ¥2,489,564,000, which significantly exceeds its total liabilities of ¥589,756,000, resulting in a current ratio of 14.68. The company is debt-free, with no long-term debt, and its debt-to-equity ratio is 0.0, indicating no leverage in its capital structure.

The company is currently unprofitable, with a net loss of ¥196,732,000 and an operating loss of ¥198,154,000. Its return on equity is -8.47% and return on assets is -6.76%, both significantly below the industry norms for profitability and returns. These metrics suggest that the company is not generating returns on its equity or assets and is likely in a high R&D or development phase.

Kringle Pharma Inc's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided. The absence of segment or geographic diversification increases the company's exposure to market-specific risks, particularly in the healthcare diagnostics industry.

The company's growth trajectory is uncertain, as it has reported a significant operating and net loss. There are no disclosed revenue growth rates or outlooks for the current or next fiscal year, and the company's operating cash flow is negative at ¥315,254,000, indicating that it is not generating sufficient cash from operations to sustain its activities.

Risk factors for Kringle Pharma Inc include its unprofitability and negative cash flow from operations. The company has no immediate filing-based liquidity or dilution flags, and its dilution potential is assessed as low. However, the absence of profitability and the need for continued R&D investment could lead to future dilution if the company requires additional capital.

Recent events for Kringle Pharma Inc include the latest financial filing, which shows a significant operating and net loss. There are no disclosed recent earnings calls, investor presentations, or other public communications that provide additional insight into the company's strategic direction or operational performance.

Key takeaways

Kringle Pharma Inc is a biotechnology company with a focus on healthcare diagnostics, currently in a high R&D or development phase.
The company has a highly liquid capital structure with no long-term debt and a current ratio of 14.68.
Kringle Pharma Inc is unprofitable, with a net loss of ¥196,732,000 and a return on equity of -8.47%.
The company's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
Kringle Pharma Inc has no immediate liquidity or dilution flags, but its unprofitability and negative cash flow from operations pose ongoing risks.

Bull / Bear case

Generated · model-assisted

BULL CASE · 4

The company maintains zero long-term debt, resulting in a debt-to-equity ratio significantly above the cohort median.

Cash conversion metrics are rated best in class, significantly exceeding the cohort median of 0.87.

Dilution and liquidity risks are assessed as low, providing a stable capital structure environment.

Operating losses narrowed to 357.88 million yen in FY-4, showing improvement from prior periods.

BEAR CASE · 1

The company faces high credit risk, signaling potential difficulties in meeting financial obligations.

In focus — financials by report

Valuation FY

Market price

¥293,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

¥2.32B

Net cashⓘ

¥2.49B

Current ratioⓘ

14.7

Debt / equityⓘ

0.0

ROAⓘ

-6.8%

ROEⓘ

-8.5%

Cash conversionⓘ

160.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-814,1 %Below median

Net Margin-808,3 %Below median

ROE-8,5 %Above median

D/E0,00Above median

Cash Conv1,60Best in class

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income
Return On Assets
net_income / total_assets

Source documents

Kringle Pharma Inc Market data — financials · 2026-05-26

Ownership & reference

Leadership

Kunio IwataniPresident & CEO

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

4884.TCanonical

Tokyo Stock Exchange · JPY

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread